Remnant Cholesterol Predicts Long-term Mortality of Patients With Metabolic Dysfunction–associated Fatty Liver Disease
Authors:
- 6 May 2022
- journal article
- research article
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 107 (8) , e3295-e3303
Abstract
Context Elevated serum remnant cholesterol independently predicts risks of cardiovascular diseases. However, the association between remnant cholesterol and metabolic dysfunction–associated fatty liver disease (MAFLD) remains unclear. Objective This study aimed to explore the association of remnant cholesterol with MAFLD and its long-term mortality. Methods We extracted data from the NHANES III, 1988 to1994 and the linked mortality data until December 31, 2015. The association between remnant cholesterol and MAFLD was analyzed by multivariable logistic regression. Cox proportional hazards regression was performed to assess whether elevated remnant cholesterol increased all-cause and cause-specific mortalities in MAFLD patients. Results At baseline, 28.6% (1474/5156) of participants had MAFLD. In multivariable logistic regression, the fourth quartile of remnant cholesterol was associated with an increased risk of MAFLD compared with the first quartile (odds ratio [OR]: 1.714; 95% CI, 1.586-1.971; P < .001). In participants with normal levels of triglycerides, low-density lipoprotein and high-density lipoprotein cholesterol, the relationship between remnant cholesterol and MAFLD risk remained significant (OR: 1.346; 95% CI, 1.248-1.761; P < .001). During a median follow-up of 307 months, MAFLD patients with serum remnant cholesterol in the fourth quartile were associated with a higher risk of all-cause mortality (hazard ratio [HR]: 2.183; 95% CI, 1.825-2.407; P < .001), as well as a higher risk of cardiovascular mortality (HR: 2.346; 95% CI, 2.046-2.885; P < .001) and cancer-related mortality (HR: 2.366; 95% CI, 1.864-2.932; P < .001) compared with MAFLD patients in the first quartile. Conclusion Remnant cholesterol was independently associated with the risk of MAFLD and predicted all-cause, cardiovascular, and cancer-related mortalities in MAFLD patients.Keywords
Funding Information
- National Key Research and Development Program of China (2018YFA0109800)
- National Natural Science Foundation of China (82070585)
- Key Research and Development Program of Zhejiang Province (2020C03033)
This publication has 59 references indexed in Scilit:
- Remnant cholesterol as a cause of ischemic heart disease: Evidence, definition, measurement, atherogenicity, high risk patients, and present and future treatmentPharmacology & Therapeutics, 2014
- Elevated Remnant Cholesterol Causes Both Low-Grade Inflammation and Ischemic Heart Disease, Whereas Elevated Low-Density Lipoprotein Cholesterol Causes Ischemic Heart Disease Without InflammationCirculation, 2013
- Remnant Cholesterol as a Causal Risk Factor for Ischemic Heart DiseaseJACC, 2013
- Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for managementEuropean Heart Journal, 2011
- Delayed postprandial metabolism of triglyceride-rich lipoproteins in obese young men compared to lean young menClinica Chimica Acta, 2010
- Hepatic steatosis, low-grade chronic inflammation and hormone/growth factor/adipokine imbalanceWorld Journal of Gastroenterology, 2010
- Harmonizing the Metabolic SyndromeCirculation, 2009
- The Residual Risk Reduction Initiative: A Call to Action to Reduce Residual Vascular Risk in Patients with DyslipidemiaThe American Journal of Cardiology, 2008
- Lipoprotein lipase activator ameliorates the severity of dietary steatohepatitisBiochemical and Biophysical Research Communications, 2007
- Diagnosis and Management of the Metabolic SyndromeCirculation, 2005